Introduction:
A leading pharma stock reported strong Q3FY25 results, with revenue rising 18.1% YoY and net profit surging 402.7%. Improved operational efficiency and cost management fueled investor confidence, pushing the stock to a 20% upper circuit following the impressive earnings growth.
Share Price movement of GlaxoSmithKline Pharmaceuticals:
On February 17, 2025, GlaxoSmithKline Pharmaceuticals Ltd opened at ₹2,199.95, reaching a high of ₹2,421.60 and a low of ₹2,086.50, up 19.77% from its previous close of ₹2,018.00. Currently, it is trading at ₹2,416.90, with a market cap of ₹40,943.74 crore.
GlaxoSmithKline Pharmaceuticals Q3 Results:
GlaxoSmithKline Pharmaceuticals Q3FY25 revenue increased by 18.1% YoY to ₹98,449 crore from ₹83,337 crore. However, total expenses surged by 11.9% to ₹67,639 crore. Despite higher costs, profit before tax rose significantly by 370.8% to ₹30,810 crore from ₹6,543 crore in Q3FY24.
The company’s tax expenses saw a substantial rise, with current tax increasing to ₹7,349 crore from ₹3,141 crore. Deferred tax also moved to ₹473 crore from a negative ₹1,170 crore. Even with this higher tax outflow, net profit for Q3FY25 rose 402.7% YoY to ₹22,988 crore compared to ₹4,572 crore last year.
This significant profit growth triggered a strong rally, with the stock hitting a 20% upper circuit. The remarkable increase in net profit reflects improved operational efficiency, higher sales, and cost management, leading to positive investor sentiment and renewed confidence in the company’s long-term potential.
Also Read: Navratna stock jumps after it receives LoI worth ₹6700 Cr for Singareni thermal power project
Recent news About GlaxoSmithKline Pharmaceuticals :
On February 15, 2025, GlaxoSmithKline Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its 5-in-1 meningococcal vaccine, Penmenvy, designed to protect against MenABCWY strains.
Stock performance of GlaxoSmithKline Pharmaceuticals for Period of 1 week, 6 months and 1 year:
GlaxoSmithKline Pharmaceuticals stock showed a declining trend across multiple periods. Over the past week, it dropped by 5.76%. In the last six months, the stock saw a sharper decline of 34.1%. On a yearly basis, it remained weak, falling by 10.7%, reflecting sustained pressure.
Also Read: Railway stock jumps after it receives order worth ₹466 Cr from NLC India
Shareholding pattern of GlaxoSmithKline Pharmaceuticals:
| All values in % | Dec-24 | Sep-24 | Jun-24 |
| Promoters | 75 | 75 | 75 |
| FII | 4.5 | 4.36 | 4.02 |
| DII | 7.3 | 7.34 | 7.51 |
| Retail & others | 13.21 | 13.3 | 13.48 |
About GlaxoSmithKline Pharmaceuticals:
GlaxoSmithKline Pharmaceuticals is a leading healthcare company specializing in vaccines, medicines, and consumer health products. It focuses on respiratory, oncology, and infectious diseases, contributing to global healthcare innovation while maintaining a strong presence in India’s pharmaceutical sector with advanced research and development.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
